false
0001175151
0001175151
2023-12-11
2023-12-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 11, 2023
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware |
|
001-36792 |
|
98-0373793 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
305
College Road East
Princeton, New Jersey |
08540 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (732) 329-8885
Not Applicable
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
common stock, $0.001 par value |
CTSO |
The Nasdaq Stock Market LLC (Nasdaq Capital Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 1.01 |
Entry into a Material Definitive Agreement |
On December 11, 2023, CytoSorbents Corporation
(the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and
accredited investors (collectively, the “Investors”) for the sale by the Company directly to the Investors of an aggregate
of 7,733,090 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”)
together with warrants (the “Warrants”) to purchase up to 2,706,561 shares of Common Stock (the shares of Common Stock underlying
the warrants, the “Warrant Shares”). Each Warrant has an exercise price per share of $2.00, which will be exercisable immediately
and will expire on the fifth anniversary of the original issue date. The Shares and the Warrants were sold together for a combined purchase
price of $1.33 per share and accompanying warrant to purchase 0.35 shares of Common Stock, for an aggregate gross purchase price of $10,285,009.70.
The Shares and Warrants sold in the offering include an aggregate of 327,070 Shares and 114,465 Warrants sold to the Company’s executive
officers, directors and certain non-executive officer employees of the Company.
The issuance and sale of the Shares and the Warrants
(the “Registered Direct Offering”) is expected to close on December 12, 2023, subject to customary closing conditions set
forth in the Purchase Agreement. The Company intends to use the net proceeds of the Registered Direct Offering for general corporate purposes,
including to fund clinical and regulatory efforts to file for DrugSorb-ATR marketing approval in the United States and Canada, to fund
clinical studies in the United States and Canada, to support growth initiatives for CytoSorb, to invest in clinical studies and the generation
of new clinical data, to fund ongoing R&D initiatives and further develop products, and general working capital purposes. The Company
estimates that the net proceeds from Registered Direct Offering will be approximately $9.83 million after deducting estimated transaction
fees and expenses.
The Shares, the Warrants and the Warrant Shares
(collectively, the “Securities”) were offered and sold by the Company directly to the Investors, without a placement agent,
underwriter, broker or dealer, pursuant to an effective shelf registration statement on Form S-3 (File No. 333-257910) declared effective
by the Securities and Exchange Commission (the “SEC”) on July 27, 2021, and the base prospectus contained therein. Prior to
closing, the Company will file a prospectus supplement with the SEC relating to the offer and sale of the Securities in the Registered
Direct Offering.
The Purchase Agreement contains customary representations,
warranties and agreements of the Company and the Investors, customary conditions to closing, indemnification obligations of the Company,
other obligations of the parties and termination provisions. Pursuant to the Purchase Agreement and subject to certain exceptions including
an exception for sales of Common Stock made pursuant to the Company’s at-the-market offering facility with Jefferies LLC , the Company
is subject to company lock-up restrictions on the issuance and sale of the Company’s securities for 60 days following the closing
of the Registered Direct Offering.
The representations, warranties and covenants contained
in the Purchase Agreement were made solely for the benefit of the Company and the Investors. In addition, such representations, warranties
and covenants (i) are intended as a way of allocating the risk between the Company and the Investors and not as statements of fact, and
(ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors
in, the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of
the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.
The foregoing description of the Purchase Agreement
and Warrant is not complete and is qualified in its entirety by references to the full text of the Purchase Agreement and Warrant, the
forms of which are filed herewith as Exhibit 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated by reference
herein.
This Current Report on Form 8-K does not constitute
an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or jurisdiction.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements that involve risks and uncertainties, such as statements related to the expected use of the proceeds from the Registered Direct
Offering. There are a number of important factors that could cause actual results to differ materially from those indicated or implied
by forward-looking statements. Accordingly, you are cautioned that these forward-looking statements are only predictions and are subject
to risks, uncertainties and assumptions, including those referenced from time to time in the Company’s periodic reports and other
filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s
current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to
revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise,
except as required by law.
Based on the Company’s current operating plan, which includes
the continuation or initiation of new clinical trials, the Company believes that the net proceeds from the Registered Direct Offering,
together with the Company’s existing cash and cash equivalents, will enable the Company to fund its planned operating expenses and
capital expenditures into the third quarter of 2024. The Company has based this estimate on assumptions that may prove to be wrong, and
it could utilize its available capital resources sooner than the Company currently expects. The Company continues to pursue less or non-dilutive
sources of capital, such as debt, royalty financing, licensing, and strategic partnerships, and equity that are intended to supplement
the Company’s cash position and fund the Company’s operating expenses into 2025.
(d) Exhibits
* Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv)
of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 11, 2023 |
CYTOSORBENTS CORPORATION |
|
|
|
|
By: |
/s/ Dr. Phillip P. Chan |
|
Name: |
Dr. Phillip P. Chan |
|
Title: |
Chief Executive Officer |
Exhibit 4.1
COMMON STOCK PURCHASE WARRANT
CYTOSORBENTS
CORPORATION
Warrant Shares: _______ |
Issue Date: December 12, 2023 |
THIS COMMON STOCK PURCHASE WARRANT
(the “Warrant”) certifies that, for value received, ___________________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
December 12, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 12,
2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from CytoSorbents Corporation, a Delaware
corporation (the “Company”), up to _____ shares of common stock, par value $0.001 per share (the “Common Stock”)
(as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1.
Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities
Purchase Agreement (the “Purchase Agreement”), dated December 11, 2023, among the Company and the purchasers signatory
thereto.
Section 2.
Exercise.
a) Exercise of
Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy (or.pdf
copy via e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within
the earlier of (i) two (2) days on which the Nasdaq Capital Market is open for trading (“Trading Days”) and
(ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following
the date of exercise as aforesaid, the Holder shall deliver the unpaid portion of the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the Cashless
Exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in
which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on
which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
b) Exercise Price. The exercise price per share of Common Stock
under this Warrant shall be $2.00, subject to adjustment hereunder (the “Exercise Price”).
c) Cashless Exercise.
If at any time during the term of this Warrant, there is no effective registration statement registering, or no current prospectus available
for, the issuance or resale of the Warrant Shares by the Holder, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares determined according to the following formula (a “Cashless
Exercise”):
For purposes of
the foregoing formula:
(A) = the total number of shares
with respect to which the Warrants are then being exercised.
(B) = as applicable: (i) the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both
executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in
Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of
the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
after the close of “regular trading hours” on such Trading Day; and
(C) = the Exercise Price then in
effect for the applicable Warrant Shares at the time of such exercise.
If Warrant Shares are issued in such a cashless
exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares
shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to
this Section 2(c). Notwithstanding anything to the contrary, without limiting the rights of
the Holder to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in the event the
Company does not have or maintain an effective registration statement, there are no circumstances that would require the Company to make
any cash payments or net cash settle the purchase warrants to the holders.
“Bid Price”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New
York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets”
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
“Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any
successors to any of the foregoing).
“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the
“Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market
value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest
of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
Notwithstanding anything herein to the contrary,
on the Termination Date, this Warrant shall be automatically be terminated.
d) Mechanics
of Exercise.
i. Delivery of
Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by the
transfer agent of the Company (the “Transfer Agent”) crediting the account of the Holder’s or its designee’s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if
the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant is being exercised via Cashless Exercise,
and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its
designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a Cashless Exercise) is received
within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin
to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such
exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a
number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.
ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.
iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.
v. No Fractional
Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.
vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
e) Reserved.
Section 3.
Certain Adjustments.
a) Stock Dividends
and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b) Reserved.
c) Reserved.
d) Pro Rata Distributions.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution
e) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of shares of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on
the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of shares of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior
to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.
f) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
g) Notice to
Holder.
i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
ii. Notice to
Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the shares
of Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the shares of Common Stock,
(C) the Company shall authorize the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or
purchase any capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in
connection with any reclassification of the shares of Common Stock, any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the shares of Common Stock
are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email
to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 5 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to
be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or stock exchange is expected
to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled
to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or stock exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice and provided, further that no notice shall
be required if the information is disseminated in a press release or document filed with the Securities and Exchange Commission . To the
extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.
Section 4.
Transfer of Warrant.
a) Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to
the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.
b) New Warrants.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the
Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.
c) Warrant Register.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.
Section 5.
Miscellaneous.
a) No Rights
as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
b) Loss, Theft,
Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.
d) Authorized
Shares.
The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the shares of Common Stock may be listed. The Company covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue).
Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.
Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.
e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.
f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize Cashless Exercise, will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that the Holder’s
right to exercise this Warrant terminates on the Termination Date. If the Company willfully and knowingly fails to comply with any provision
of this Warrant or the Purchase Agreement, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of
its rights, powers or remedies hereunder.
h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.
i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.
j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.
k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.
l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
********************
(Signature Page Follows)
IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
|
CYTOSORBENTS CORPORATION |
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Exhibit A
NOTICE OF EXERCISE
|
TO: |
CYTOSORBENTS CORPORATION |
(1) The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the Exercise Price in full, together with all applicable transfer taxes, if any.
(2) Payment shall take
the form of (check applicable box):
[ ] in lawful money of the
United States; or
[ ] if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the Cashless Exercise procedure set forth in subsection 2(c).
(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following
DWAC Account Number:
(4) Accredited Investor.
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.
_____________________
_____________________
[SIGNATURE
OF HOLDER]
Name of Investing Entity: ________________________________________________________________________
Signature
of Authorized Signatory of Investing Entity: _________________________________________________
Name of Authorized Signatory: ___________________________________________________________________
Title of Authorized Signatory: ____________________________________________________________________
Date: ________________________________________________________________________________________
Exhibit B
ASSIGNMENT FORM
(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to
Name: |
|
|
|
|
(Please Print) |
Address: |
|
|
|
|
(Please Print) |
|
|
|
Phone Number: |
|
|
|
|
|
Email Address: |
|
|
|
|
|
Dated: _______________ __, ______ |
|
|
|
|
|
Holder’s Signature:______________________ |
|
|
|
|
|
Holder’s Address:______________________ |
|
|
Exhibit 10.1
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
SECURITIES PURCHASE AGREEMENT
SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of December 11, 2023, by and among CYTOSORBENTS
CORPORATION, a Delaware corporation (the “Company”), and the investors identified on Schedule I hereto
(each, an “Investor” and collectively, the “Investors”).
WHEREAS:
Subject to the terms and conditions set
forth in this Agreement, the Company wishes to sell to the Investors, and the Investors, severally and not jointly, wish
to buy from the Company, (i) the shares listed on Schedule I hereto (the “Purchase Shares”) of the
Company's common stock, $0.001 par value per share (the “Common Stock”), and (ii) warrants to purchase
shares of Common Stock listed on Schedule I hereto issuable upon exercise of the Warrants (as defined below) (the
“Warrant Shares”, and together with the Purchase Shares, the “Securities”), for an aggregate
purchase price of $10,285,009.70.
NOW THEREFORE, in consideration of the mutual
covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the Company and the Investors hereby agree as follows:
1. CERTAIN
DEFINITIONS.
For purposes of this Agreement,
the following terms shall have the following meanings:
(a) “Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.
(b) “Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
(c) “Base
Prospectus” means the Company’s base prospectus, dated July 27, 2021, which is included in the Registration Statement,
including the documents incorporated by reference therein.
(d) “Business
Day” means any day on which the Principal Market is open for trading, including any day on which the Principal Market is open
for trading for a period of time less than the customary time.
(e) “Closing
Date” has the meaning ascribed to such term in Section 2(a) hereof.
(f) “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
(g) “DTC”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.
(h) “DWAC
Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable
and without restriction on resale and (iii) timely credited by the Company to the Investor or its designee’s specified Deposit/Withdrawal
at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar program hereafter adopted
by DTC performing substantially the same function.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(i) “Escrow
Agent” means Equiniti Trust Company, LLC, a New York limited liability corporation.
(j) “Escrow
Agreement” means the escrow agreement entered into on or prior to the date hereof, by and between the Company and the Escrow
Agent, pursuant to which the Investors shall deposit Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated
hereunder.
(k) “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
(l) “Initial
Prospectus Supplement” means the prospectus supplement of the Company relating to the Securities, including the accompanying
Base Prospectus, to be prepared and filed by the Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act and
in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference.
(m) “Material
Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the
results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any
material adverse effect that resulted primarily from (A) any change in the United States or foreign economies or securities or financial
markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any change
that generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on
the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes, hostilities, acts of
war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage
or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor, its Affiliates or its successors
and assigns with respect to the transactions contemplated by this Agreement, (E) the effect of any change in applicable laws or
accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (F) any
change resulting from compliance with terms of this Agreement or the consummation of the transactions contemplated by this Agreement,
or (G) any change, in and of itself, in the Company’s stock price or trading volume from and after the date hereof (provided,
however, that the facts and circumstances underlying any such change may, except as may be provided in subsections (A), (B), (C) (D),
(E) or (F) of this definition, be considered in determining whether a Material Adverse Effect has occurred), or (iii) the
Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document to be performed
as of the date of determination.
(n) “Person”
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.
(o) “Principal
Market” means The Nasdaq Capital Market (or any nationally recognized successor thereto); provided, however, that in the event
the Company’s Common Stock is ever listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York
Stock Exchange, the NYSE American, the NYSE Arca, the OTC Bulletin Board, or the OTCQX or the OTCQB operated by the OTC Markets Group, Inc.
(or any nationally recognized successor to any of the foregoing), then the “Principal Market” shall mean such other market
or exchange on which the Company’s Common Stock is then listed or traded.
(p) “Prospectus”
means the Base Prospectus, as supplemented by any Prospectus Supplement (including the Initial Prospectus Supplement), including the
documents and information incorporated by reference therein.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(q) “Prospectus
Supplement” means any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed with
the SEC pursuant to Rule 424(b) under the Securities Act in connection with the transactions contemplated by this Agreement,
including the documents and information incorporated by reference therein.
(r) “Registration
Statement” means the effective registration statement on Form S-3 (SEC File No. 333-257910), including all amendments
thereto, filed by the Company with the SEC pursuant to the Securities Act for the registration of shares of its Common Stock, including
the Securities, and certain other securities, as such Registration Statement has been or may be amended and supplemented from time to
time, including all documents filed as part thereof or incorporated by reference therein, and including all information deemed to be
a part thereof at the time of effectiveness pursuant to Rule 430B of the Securities Act, including any comparable successor registration
statement filed by the Company with the SEC pursuant to the Securities Act for the registration of shares of its Common Stock, including
the Securities.
(s) “SEC”
means the U.S. Securities and Exchange Commission.
(t) “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
(u) “Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting
stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under
the Securities Act.
(v) “Transaction
Documents” means, collectively, this Agreement, the Warrant, the Escrow Agreement and the schedules and exhibits hereto
and thereto, and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties
hereto in connection with the transactions contemplated hereby and thereby.
(w) “Warrant”
means the Common Stock purchase warrants delivered to the Investors at the Closing, which Warrants shall have the terms and conditions
set forth in the form of Warrant attached as Exhibit A hereto.
(x) “Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.
2. PURCHASE OF SECURITIES.
Subject to the terms and
conditions set forth in this Agreement, the Company desires to sell to each Investor, and each Investor, severally and not jointly,
desires to purchase from the Company, the Securities as follows:
(a) Delivery
of Securities. On the Closing Date, which shall be the first (1st) Business Day after the date hereof, upon satisfaction
of the conditions to Closing set forth in Sections 7 and 8 hereof, the Company shall deliver to each Investor its respective Purchase
Shares and Warrants set forth opposite their respective names on Schedule I hereto (the “Closing”). The Closing
shall occur at 10:00 a.m., Eastern time, on the Closing Date or at such other time, date and location as the parties may agree in writing.
(b) Payment
of Purchase Price. On the Closing Date, each of the Investors shall pay the amount of cash for the number of Securities it is
purchasing hereunder set forth opposite its name on Schedule I hereto (with respect to each Investor, such Investor’s
“Subscription Amount”). Each Investor shall deliver to the account designated by the Escrow Agent, via wire
transfer, immediately available funds in lawful money of the United States of America equal to such Investor’s Subscription
Amount.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
3. INVESTORS’
REPRESENTATIONS AND WARRANTIES.
Each Investor, severally
and only with respect to itself and not jointly, represents and warrants to the Company that as of the date hereof and as of the Closing
Date:
(a) Organization,
Authority. Such Investor is either an individual or an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization, with the requisite power and authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder and thereunder.
(b) Accredited
Investor Status. Such Investor is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation
D promulgated under the Securities Act.
(c) Information.
Such Investor understands that its investment in the Securities involves a high degree of risk. Such Investor (i) is able to bear
the economic risk of an investment in the Securities including a total loss thereof, (ii) has such knowledge and experience in financial
and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has
had an opportunity to ask questions of and receive answers from the officers of the Company concerning the financial condition and business
of the Company and others matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations
conducted by such Investor or its representatives shall modify, amend or affect such Investor's right to rely on the Company's representations
and warranties contained in Section 4 below. Such Investor has sought such accounting, legal and tax advice from its own
independent advisors as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.
(d) No
Governmental Review. Such Investor understands that no U.S. federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of an investment in the Securities
nor have such authorities passed upon or endorsed the merits of the offering of the Securities.
(e) Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of such Investor and is a valid
and binding agreement of such Investor enforceable against the Investor in accordance with its terms, subject as to enforceability to
general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws
relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies.
(f) Residency.
Such Investor is a resident of or is organized in the state set forth opposite such Investor’s name on Schedule I hereto.
(g) Insider
Trading and Public Disclosure Laws. Investor acknowledges that Investor has become aware of material, non-public information concerning
the Company in the course of the discussions regarding the transactions contemplated herein and Investor represents and warrants that
such Investor has not (i) disclosed or “tipped” material, non-public information concerning the Company to any person
or entity, (ii) effected or participated in any trading of any securities (or beneficial ownership thereof) of the Company while
in possession of material, non-public information concerning the Company or (iii) taken any action that might force the Company
to make a public announcement under applicable securities laws. The Company agrees that the Initial Prospectus Supplement shall contain and disclose publicly any material nonpublic information provided
by the Company to the Investor and that Investor will no longer be restricted from trading in the securities of the Company.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
4. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.
The Company represents and
warrants to the Investors that, except as set forth in the disclosure schedules attached hereto, which exceptions shall be deemed to
be a part of the representations and warranties made hereunder, as of the date hereof and as of the Closing Date:
(a) Registration
Statement. The Registration Statement in respect of the Securities has been filed with the SEC pursuant to Rule 415 under the
Securities Act. The Company meets the requirements for use of Form S-3 under the Securities Act, and the rules and regulations
of the SEC thereunder (the “Rules and Regulations”). The Registration Statement delivered to the Investors or
made available, and, excluding exhibits thereto, to the Investors, have been declared effective by the SEC in such form and meet the
requirements of the Securities Act, and the Rules and Regulations. The proposed offering of the Securities may be made pursuant
to General Instruction I.B.1 of Form S-3. Other than (i) the Registration Statement, (ii) a registration statement, if
any, increasing the size of the offering filed pursuant to Rule 462(b) under the Securities Act and the Rules and Regulations
(a “Rule 462(b) Registration Statement”), and (iii) the Prospectus contemplated by this Agreement to
be filed pursuant to Rule 424(b) of the Rules and Regulations, no other document with respect to the offer and sale of
the Securities has heretofore been filed with the SEC. No stop order suspending the effectiveness of the Registration Statement or the
Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A
of the Securities Act has been initiated or, to the Company’s knowledge after reasonable investigation and due diligence inquiry
(“Knowledge”), threatened by the SEC. Any reference herein to the Registration Statement, Base Prospectus or the Prospectus
shall be deemed to refer to and include the documents incorporated by reference therein. Any reference to any amendment or supplement
to any Base Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after the date of such Base Prospectus
or the Prospectus under the Exchange Act, and incorporated by reference in such Base Prospectus or Prospectus, as the case may be. Any
reference to (i) the Registration Statement shall be deemed to refer to and include the annual report of the last completed fiscal
year of the Company on Form 10-K filed under Section 13(a) or 15(d) of the Exchange Act prior to the date hereof
and (ii) the effective date of such Registration Statement shall be deemed to refer to and include the date such Registration Statement
became effective and, if later, the date such Form 10-K was so filed. Any reference to any amendment to the Registration Statement
shall be deemed to refer to and include any annual report of the Company filed pursuant to Section 13(a) or 15(d) of the
Exchange Act after the date of this Agreement that is incorporated by reference in the Registration Statement.
(b) No
Stop Orders; No Material Misstatements. No order preventing or suspending the use of the Prospectus relating to the proposed offering
of the Securities has been issued by the SEC, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act
has been instituted or, to the Company’s Knowledge, threatened by the SEC, and the Prospectus, at the time of filing thereof, conformed
in all material respects to the requirements of the Securities Act and the Rules and Regulations, and did not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.
(c) Registration
Statement and Prospectus Contents. At the respective times the Registration Statement and any amendments thereto became or become
effective the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects
to the requirements of the Securities Act and the Rules and Regulations and did not and will not contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and
Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The Prospectus contains or
will contain all required information under Rule 430B.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(d) Documents
Incorporated by Reference/Disclosure of Agreements.
a. The Company has filed all reports, schedules, forms, statements and
other documents required to be filed by the Company under the Securities Act and Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
together with the Prospectus, being collectively referred to herein as the “SEC Reports”) on a timely basis
or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The Company is not, and has never been, an issuer subject to Rule 144(i)(1) of
the Securities Act.
The documents incorporated by reference in the
Prospectus, when they were filed with the SEC, conformed in all material respects to the requirements of the Securities Act or the Exchange
Act, as applicable, and the rules and regulations of the SEC thereunder and none of such documents contained any untrue statement
of a material fact or omitted to state any material fact required to be stated therein, or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by
reference in the Prospectus, when such documents are filed with SEC will conform in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the SEC thereunder and will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
b. The agreements and documents described
in the Registration Statement and the Prospectus conform in all material respects to the descriptions thereof contained or incorporated
by reference therein, and there are no agreements or other documents required by the Securities Act and the Securities Act Regulations
to be described in the Registration Statement and the Prospectus or to be filed with the SEC as exhibits to the Registration Statement
or to be incorporated by reference in the Registration Statement and the Prospectus, that have not been so described or filed or incorporated
by reference. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it
is or may be bound or affected and (i) that is referred to or incorporated by reference in the Registration Statement or the Prospectus,
or (ii) is material to the Company’s business, has been duly authorized and validly executed by the Company, is in full force
and effect in all material respects and is enforceable against the Company and, to the Company’s Knowledge, the other parties thereto,
in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar
laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution provision may be
limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor
may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company’s
Knowledge, any other party is in default thereunder and, to the Company’s Knowledge, no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a default thereunder except for a default or event which would not reasonably
be expected to result in a Material Adverse Effect. To the best of the Company’s Knowledge, performance by the Company of the material
provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment,
order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or
businesses, including, without limitation, those relating to environmental laws and regulations.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(e) Distribution
of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute any offering material in
connection with the offering and sale of the Securities other than the Prospectus and other materials, if any, permitted under the Securities
Act and as provided herein.
(f) Not
an Ineligible Issuer. At the time of filing the Registration Statement, any Rule 462(b) Registration Statement and any
post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an “ineligible
issuer,” as defined in Rule 405 of the Rules and Regulations.
(g) Organization
and Good Standing. The Company and each of its Subsidiaries (as defined in Rule 405 of the Rules and Regulations) have
been duly organized and are validly existing as corporations or other legal entities in good standing (or the foreign equivalent thereof)
under the laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly qualified to do business
and are in good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or
lease of property or the conduct of their respective businesses requires such qualification and have all power and authority (corporate
or other) necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where
the failure to so qualify or have such power or authority would not reasonably be expected to (i) have, singularly or in the aggregate,
a Material Adverse Effect on the business, properties, management, financial position, stockholders’ equity, results of operations
or prospects of the Company and its Subsidiaries taken as a whole, or (ii) impair in any material respect the ability of the Company
to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement or the Prospectus. Other
than CytoSorbents Medical UK Limited, the Company does not own or control, directly or indirectly, any corporation, association or other
entity other than the subsidiaries listed in Exhibit 21 to the Company’s most recent Annual Report on Form 10-K.
(h) The
Common Stock. The Common Stock, including the Purchase Shares and any Warrant Shares, to be issued and sold by the Company to the
Investors hereunder has been duly and validly authorized and, when issued and delivered against payment therefor as provided herein or,
in the case of the Warrant Shares, as provided in the warrant agreements, will be duly and validly issued, fully paid and non-assessable
and will conform to the descriptions thereof in the Registration Statement and the Prospectus; and the issuance of the Common Stock is
not subject to any preemptive or similar rights.
(i) Capitalization.
All of the issued shares of capital stock of the Company, have been duly and validly authorized and issued, are fully paid and non-assessable,
have been issued in compliance with federal and state securities laws, and conform in all material respects to the description thereof
contained in the Prospectus under the heading “Description of Capital Stock.” All of the Company’s options, warrants
and other rights to purchase or exchange any securities for shares of the Company’s capital stock have been duly authorized and
validly issued and were issued in compliance with federal and state securities laws. None of the outstanding shares of Common Stock was
issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities
of the Company. As of the date hereof, there were no authorized or outstanding shares of capital stock, options, warrants, preemptive
rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable
for, any capital stock of the Company or any of its Subsidiaries other than those described above or accurately described in the Prospectus.
Since the date hereof, the Company has not issued any securities other than Common Stock issued pursuant to the exercise of warrants
or upon the exercise of stock options or other awards outstanding under the Company’s stock option plans, options or other securities
granted or issued pursuant to the Company’s existing equity compensation plans or other plans, and the issuance of Common Stock
pursuant to employee stock purchase plans. The description of the Company’s stock option, stock bonus and other stock plans or
arrangements, and the options or other rights granted thereunder, as described in the Prospectus, accurately and fairly present in all
material respects the information required to be shown with respect to such plans, arrangements, options and rights. The Company does
not have a corporate credit rating or debt securities rated by any “nationally recognized statistical rating organization,”
as that term is defined by the SEC for purposes of Rule 436(g)(2) of the Rules and Regulations.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(j) Capitalization
of Subsidiaries. All the outstanding shares of capital stock (if any) of each Subsidiary of the Company have been duly authorized
and validly issued, are fully paid and nonassessable and, except to the extent set forth in the Prospectus, are owned by the Company
directly or indirectly through one or more wholly-owned Subsidiaries, free and clear of any claim, lien, encumbrance, security interest,
restriction upon voting or transfer or any other claim of any third party.
(k) No
Conflicts. The execution, delivery and performance of this Agreement by the Company, the issue and sale of the Securities by the
Company and the consummation of the transactions contemplated by this Agreement will not (with or without notice or lapse of time or
both) (i) conflict with or result in a breach or violation of any of the terms or provisions of, constitute a default or a Debt
Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, encumbrance, security interest,
claim or charge upon any property or assets of the Company or any Subsidiary pursuant to, any indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any
of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject, (ii) result
in any violation of the provisions of the charter or by-laws (or analogous governing instruments, as applicable) of the Company or any
of its Subsidiaries or (iii) result in the violation of any law, statute, rule, regulation, judgment, order or decree of any court
or governmental or regulatory agency or authority, domestic or foreign, having jurisdiction over the Company or any of its Subsidiaries
or any of their properties or assets except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation
or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. A “Debt
Repayment Triggering Event” means any event or condition that gives, or with the giving of notice or lapse of time would give
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to
require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company of any of its Subsidiaries.
(l) No
Consents Required. Except for the registration of the Securities under the Securities Act and applicable state securities laws, and
such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory
Authority (“FINRA”) and the Nasdaq Capital Market in connection with the purchase and distribution of the Securities
by the Investors and the listing of the Securities on the Nasdaq Capital Market, no consent, approval, authorization or order of, or
filing, qualification or registration (each an “Authorization”) with, any court, governmental or regulatory agency
or authority, foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is required for the
execution, delivery and performance of this Agreement by the Company, the issuance and sale of the Securities or the consummation of
the transactions contemplated hereby; and no event has occurred that allows or results in, or after notice or lapse of time or both would
allow or result in, revocation, suspension, termination or invalidation of any such Authorization or any other impairment of the rights
of the holder or maker of any such Authorization.
(m) Acknowledgment
Regarding Investors’ Status. The Company acknowledges and agrees that each of the Investors are acting solely in the capacity
of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company
further acknowledges that none of the Investors are acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by any of the Investors
or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
and thereby is merely incidental to such Investor's purchase of the Securities. The Company further represents to each of the Investors
that the Company's decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Company
and its representatives and advisors.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(n) Financial
Statements. The financial statements, together with the related notes, included or incorporated by reference in the Prospectus and
in the Registration Statement fairly present, in all material respects, the financial position and the results of operations and changes
in financial position of the Company and its consolidated Subsidiaries at the respective dates or for the respective periods therein
specified. Such statements and related notes have been prepared in accordance with the generally accepted accounting principles in the
United States (“GAAP”) applied on a consistent basis throughout the periods involved except as may be set forth in
the related notes included or incorporated by reference in the Prospectus. The financial statements, together with the related notes,
included or incorporated by reference in the Prospectus comply in all material respects with Regulation S-X. No other financial statements
or supporting schedules or exhibits are required by Regulation S-X to be described, included or incorporated by reference in the Registration
Statement or the Prospectus. All information contained in the Registration Statement and the Prospectus regarding “non-GAAP financial
measures” (as defined in Regulation G) complies with Regulation G and Item 10 of Regulations S-K, to the extent applicable.
(o) eXtensible
Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance
with the SEC’s rules and guidelines applicable thereto.
(p) No
Material Adverse Change. Neither the Company nor any of its Subsidiaries has sustained, since the date of the latest audited financial
statements included or incorporated by reference in the Prospectus, (i) any material loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or action, order or decree of
any court or governmental or regulatory authority, otherwise than as set forth or contemplated in the Prospectus; (ii) any material
change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described
as outstanding in, and the grant of options and awards under the Company’s existing equity incentive plans described in, the Registration
statement and the Prospectus) or long-term debt of the Company or any of its Subsidiaries, or any dividend or distribution of any kind
declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse changes, or any development
involving a prospective material adverse change, in or affecting the business, properties, assets, general affairs, management, financial
position, prospects, stockholders’ equity or results of operations of the Company and its Subsidiaries taken as a whole, otherwise
than as set forth or contemplated in the Prospectus.
(q) Legal
Proceedings. Except as set forth in the Prospectus, there is no legal or governmental proceeding to which the Company or any of its
Subsidiaries is a party or of which any property or assets of the Company or any of its Subsidiaries is the subject, including any proceeding
before the United States Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”),
European Medicines Agency (“EMA”) or comparable federal, state, local or foreign governmental authorities (it being
understood that the interaction between the Company and the FDA, the EMA and such comparable governmental authorities relating to the
clinical development and product approval process shall not be deemed proceedings for purposes of this representation), which is required
to be described in the Registration Statement or the Prospectus and is not described therein, or which, singularly or in the aggregate,
if determined adversely to the Company or any of its Subsidiaries, could reasonably be expected to have a Material Adverse Effect; and
no such proceedings are threatened or, to the Company’s Knowledge, contemplated by governmental or regulatory authorities or threatened
by others. The Company is in compliance with all federal, state, local and foreign laws, regulations, orders and decrees currently applicable
to its business as prescribed by the FDA, EMA or any other federal, state or foreign agencies or bodies engaged in the regulation of
medical devices, except where noncompliance would not, singly or in the aggregate, have a Material Adverse Effect. All preclinical and
clinical studies conducted by or on behalf of the Company to support approval for commercialization of the Company’s products have
been conducted by the Company, or to the Company’s Knowledge by third parties, in compliance with all applicable federal, state
or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance that would not reasonably be
expected to have, singly or in the aggregate, a Material Adverse Effect.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(r) No
Violation or Default. Neither the Company nor any of its Subsidiaries is (i) in violation of its charter or by-laws (or analogous
governing instrument, as applicable), (ii) in default in any respect, and no event has occurred which, with notice or lapse of time
or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to
which any of its property or assets is subject or (iii) in violation in any respect of any law, ordinance, governmental rule, regulation
or court order, decree or judgment to which it or its property or assets may be subject (including, without limitation, those administered
by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed
by the FDA) except, in the case of clauses (ii) and (iii) above, for any such violation or default that would not reasonably
be expected to have, singularly or in the aggregate, have a Material Adverse Effect.
(s) Licenses
or Permits; Regulatory Compliance. The Company and each of its Subsidiaries possess all licenses, certificates, authorizations and
permits issued by, and have made all declarations and filings with, the appropriate local, state, federal or foreign governmental or
regulatory agencies or bodies including, without limitation, those administered by the FDA, EMA or by any foreign, federal, state or
local governmental or regulatory authority performing functions similar to those performed by the FDA that are required for the ownership
or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement and
the Prospectus (collectively, the “Governmental Permits”) except where any failures to possess or make the same would
not, singularly or in the aggregate, have a Material Adverse Effect. The Company and its Subsidiaries are in compliance, in all material
respects, with all such Governmental Permits; all such Governmental Permits are valid and in full force and effect, except where the
validity or failure to be in full force and effect would not, singularly or in the aggregate, have a Material Adverse Effect. Neither
the Company nor any Subsidiary has received written notification of any revocation, modification, suspension, termination or invalidation
(or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental
Permit will not be renewed. The Company, its Subsidiaries, and to the Company’s Knowledge, its directors, officers, employees and
agents, are and have been in compliance in all material respects with applicable federal, state, local and foreign health care regulatory
laws, rules, and regulations, including without limitation, laws related to fraud and abuse, payment transparency, and privacy and security
of protected health information (collectively, “Health Care Laws”). The Company has not received any written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court, arbitrator or
governmental or regulatory authority or third party alleging or asserting that the Company or its personnel has violated or otherwise
is in non-compliance with any Health Care Laws, nor, to the Company’s Knowledge, have any such claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action been threatened. The Company is not a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory
authority. In addition, none of the Company, its Subsidiaries or any of their respective directors, officers or employees is or, has
been debarred, suspended or excluded, or has been convicted of any crime or, to the Knowledge of the Company or its Subsidiaries, engaged
in any conduct that would result in a debarment, suspension or exclusion from any federal or state government health care program or
human clinical research, or to the Knowledge of the Company or its Subsidiaries, is subject to any inquiry, investigation, proceeding,
or other similar action by a governmental authority that could reasonably be expected to result in any such debarment, suspension, or
exclusion.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(t) Investment
Company Act. Neither the Company nor any of its Subsidiaries is or, after giving effect to the offering of the Securities and the
application of the net proceeds thereof as described in the Prospectus, will be required to register as an “investment company”
or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940,
as amended, and the rules and regulations of the SEC thereunder.
(u) No
Stabilization. Neither the Company nor, to the Company’s Knowledge, any of its officers, directors or Affiliates has taken
or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company,
or which caused or resulted in, or which might in the future reasonably be expected to cause or result in, stabilization or manipulation
of the price of any security of the Company.
(v) Intellectual
Property. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries own, possess, license
or have other rights to use all foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations,
trade names, copyrights, copyright registrations, licenses, inventions, trade secrets, technology, Internet domain names, know-how
and other intellectual property (collectively, the “Intellectual Property”), necessary for the conduct of their respective
businesses as now conducted, and as proposed to be conducted as described in the Registration Statement and the Prospectus, except to
the extent that the failure to own, possess, license or otherwise hold adequate rights to use such Intellectual Property would not, individually
or in the aggregate, have a Material Adverse Effect. To the Company’s Knowledge, the Company’s and its respective Subsidiaries’
businesses as now conducted and as proposed to be conducted as described in the Registration Statement and the Prospectus do not and
will not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property
rights of any other person. Except as disclosed in the Registration Statement and the Prospectus (i) there are no rights of third
parties to any such Intellectual Property owned by the Company and its Subsidiaries, including no liens, security interests, or other
encumbrances; (ii) to the Company’s Knowledge, there is no infringement by third parties of any such Intellectual Property
owned by the Company and its Subsidiaries; (iii) there is no pending or, to the Company’s Knowledge, threatened action, suit,
proceeding or claim by others challenging the Company’s and its Subsidiaries’ rights in or to any such Intellectual Property,
and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv) there
is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging the validity,
enforceability, or scope of any such Intellectual Property, including no interference, derivation, opposition, reexamination, or other
government proceeding and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding
or claim; (v) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others that
the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade secret or other proprietary rights
of others, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim;
(vi) to the Company’s Knowledge, there are no material defects in any of the patents or patent applications disclosed in the
Registration Statement and the Prospectus as being owned by the Company and its Subsidiaries; (vii) the Company and its Subsidiaries
have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or such Subsidiary,
and all such agreements are in full force and effect, except, in the case of any of clauses (i)-(vii) above, for any such infringement
by third parties or any such pending or threatened suit, action, proceeding or claim as would not, individually or in the aggregate,
result in a Material Adverse Effect; (viii) the Company and its Subsidiaries have taken all reasonable steps to protect, maintain
and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention
assignment agreements and invention assignments with their employees, and to the Company’s Knowledge, no employee of the Company
is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee’s employment with the Company; and (ix) to the Company’s Knowledge, the duty
of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents
and patent applications included in the Intellectual Property owned by the Company and its Subsidiaries have been complied with, and
in all foreign offices having similar requirements, all such requirements have been complied with.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(w) Title
to Real and Personal Property. The Company and each of its Subsidiaries have good and marketable title in and (in the case of real
property) to, or have valid and marketable rights to lease or otherwise use, all items of real or personal property which are material
to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security
interests, claims and defects that (i) do not, singularly or in the aggregate, materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company or any of its Subsidiaries or (ii) could
not reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect.
(x) No
Labor Dispute. There is (A) no significant unfair labor practice complaint pending against the Company, or any of its Subsidiaries,
nor to the Company’s Knowledge, threatened against it or any of its Subsidiaries, before the National Labor Relations Board, any
state or local labor relation board or any foreign labor relations board, and no significant grievance or significant arbitration proceeding
arising out of or under any collective bargaining agreement is so pending against the Company or any of its Subsidiaries, or, to the
Company’s Knowledge, threatened against it and (B) no labor disturbance by or dispute with, employees of the Company or any
of its Subsidiaries exists or, to the Company’s Knowledge, is contemplated or threatened, and the Company is not aware of any existing
or imminent labor disturbance by the employees of any of its or its Subsidiaries’ principal suppliers, manufacturers, customers
or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is
not aware that any key employee or significant group of employees of the Company or any Subsidiary plans to terminate employment with
the Company or any such Subsidiary.
(y) Environmental
Laws and Hazardous Materials. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules,
laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of
health and safety or the environment which are applicable to their businesses (the “Environmental Laws”). There has
been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic
or other wastes or other hazardous substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company’s
Knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any
of the property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any other property, in violation
of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance,
rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability; and there has
been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property
of any toxic or other wastes or other hazardous substances with respect to which the Company or any of its Subsidiaries has Knowledge.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(z) Taxes.
The Company and its Subsidiaries each (i) have timely filed all necessary federal, state, local and foreign tax returns, and all
such returns were true, complete and correct, (ii) have paid all federal, state, local and foreign taxes due and payable, for which
it is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its Subsidiaries is obligated
to withhold from amounts owing to employees, creditors and third parties, and (iii) do not have any tax deficiency or claims outstanding
or assessed or, to its Knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii) and
(iii) above, that would not, singularly or in the aggregate, have a Material Adverse Effect.
(aa) Insurance.
The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as is adequate for
the conduct of their respective businesses and the value of their respective properties. Neither the Company nor any of its Subsidiaries
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to
have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received written notice from any insurer, agent of
such insurer or the broker of the Company or any of its Subsidiaries that any material capital improvements or any other material expenditures
(other than premium payments) are required or necessary to be made in order to continue such insurance.
(bb) Disclosure
Controls. The Company and its Subsidiaries maintain disclosure controls and procedures (as such is defined in Rule 13a-15(e) of
the Exchange Act Rules) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed
to ensure that information required to be disclosed by the Company and its Subsidiaries in reports that they file or submit under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms,
including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management
to allow timely decisions regarding disclosures. The Company and its Subsidiaries have conducted evaluations of the effectiveness of
their disclosure controls as required by Rule 13a-15 of the Exchange Act.
(cc) No
Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its Subsidiaries on
the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or any
of its Affiliates on the other hand, which is required to be described in the Prospectus or a document incorporated by reference therein
and which is not so described.
(dd) No
Registration Rights. No person or entity has the right to require registration of shares of Common Stock or other securities of the
Company or any of its Subsidiaries because of the filing or effectiveness of the Registration Statement or otherwise, except for persons
and entities who have expressly waived such right in writing or who have been given timely and proper written notice and have failed
to exercise such right within the time or times required under the terms and conditions of such right. Except as described in the Prospectus,
there are no persons with registration rights or similar rights to have any securities registered by the Company or any of its Subsidiaries
under the Securities Act.
(ee) No
Broker’s Fees. Except for certain fees payable to B. Riley Securities, Inc. for serving as a financial advisor to the
Company in connection with the transactions contemplated herein, neither the Company nor any of its Subsidiaries is a party to any contract,
agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any
of its Subsidiaries or the Investors for a brokerage commission, finder’s fee or like payment in connection with the offering and
sale of the Securities or any transaction contemplated by this Agreement, the Registration Statement or the Prospectus.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(ff) Listing.
The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of
the Exchange Act. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act and is listed
on the Nasdaq Capital Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Capital Market, nor has the
Company received any notification that the SEC or FINRA is contemplating terminating such registration or listing nor has the Company
received any notification that the Nasdaq Capital Market is contemplating terminating such listing.
(gg) Sarbanes-Oxley
Act. There is and has been no failure on the part of the company or, to the Company’s Knowledge, any of the Company’s
officers or directors, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and
regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.
(hh) No
Unlawful Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any director, officer,
employee, agent or Affiliate of the Company or any Subsidiary, has (i) used any corporate funds for unlawful contributions, gifts,
entertainment or other unlawful expenses relating to political activity, (ii) made any direct or indirect unlawful payment to foreign
or domestic government officials or employees, political parties or campaigns, political party officials, or candidates for political
office from corporate funds, (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977,
as amended, or any applicable anti-corruption laws, rules, or regulations of any other jurisdiction in which the Company or any Subsidiary
conducts business, or (iv) made any other unlawful bribe, rebate, payoff, influence payment, kickback, or other unlawful payment
to any person.
(ii) Compliance
with Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as amended by Title
III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001
(USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its Subsidiaries conduct
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding
by or before any court or governmental agency, authority, body or any arbitrator involving the Company or any of its Subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the Knowledge of the Company, threatened.
(jj) Compliance
with Office of Foreign Assets Control.
a. Neither
the Company nor any of its Subsidiaries, nor, to the Company’s Knowledge, any director, officer, employee, agent or Affiliate of
the Company or any of its Subsidiaries, is a Person that is, or is owned or controlled by a Person that is: (i) the subject of any
sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United Nations Security
Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”),
nor (ii) located, organized or resident in a country or territory that is the subject of a U.S. government embargo (including, without
limitation, Cuba, Iran, North Korea, Sudan, Syria, and the Crimea). The Company has policies and procedures in place for screening counterparties with whom it conducts business against Sanctions lists and
programs.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
b. Unless
authorized by relevant government authorities, the Company will not, directly or indirectly, use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person to fund or facilitate any
activities or business of or with any Person that, at the time of such funding or facilitation is the subject of Sanctions, or in any
country or territory that, at the time of such funding or facilitation, is the subject of a U.S. government embargo; or in any other
manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter,
advisor, investor or otherwise).
(kk) No
Integrated Offering. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause
this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act, or
(ii) any applicable shareholder approval provisions of the Nasdaq.
(ll) Regulation
M Compliance. The Company has not, and to its Knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company.
(mm) DTC
Eligibility. The Company currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and the Common Stock
can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.
5. COVENANTS.
(a) Filing
of Current Report and Initial Prospectus Supplement. The Company agrees that it shall file with the SEC a report on Form 8-K
relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents (the “Current
Report”) within four Business Days of the Closing Date. The Company further agrees that it shall, within the time required
under Rule 424(b) under the Securities Act, file with the SEC the Initial Prospectus Supplement pursuant to Rule 424(b)(5) under
the Securities Act, which Initial Prospectus Supplement shall specifically relate to the Securities and shall describe the material terms
and conditions of the Transaction Documents, contain information previously omitted at the time of effectiveness of the Registration
Statement in reliance on Rule 430B under the Securities Act, and disclose all information relating to the Securities and the transactions
contemplated by the Transaction Documents required to be disclosed in the Registration Statement and the Prospectus as of the date of
the Initial Prospectus Supplement, including, without limitation, information required to be disclosed in the section captioned “Plan
of Distribution” in the Prospectus. The Company shall provide each Investor with an opportunity to review and comment upon the
final pre-filing draft versions of the Current Report and the Initial Prospectus Supplement within a reasonable time prior to their filing
with the SEC and the Company shall give reasonable consideration to all such comments. Each Investor shall use its reasonable best efforts
to comment upon the final pre-filing draft versions of the Current Report and the Initial Prospectus Supplement within a reasonable time
after such Investor receives them from the Company. Each Investor shall furnish to the Company such information regarding itself, the
Securities beneficially owned by it and the intended method of distribution thereof, including any arrangement between such Investor
and any other Person relating to the sale or distribution of the Securities, as shall be reasonably requested by the Company in connection
with the preparation and filing of the Current Report and the Initial Prospectus Supplement, and shall otherwise cooperate with the Company
as reasonably requested by the Company in connection with the preparation and filing of the Current Report and the Initial Prospectus
Supplement with the SEC.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(b) Blue
Sky. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register
or qualify (i) the offer and sale of the Securities to the Investors under this Agreement and (ii) any subsequent resale of
all Securities by the Investor, in each case, under applicable securities or “Blue Sky” laws of the states of the United
States in such states as is reasonably requested by any of the Investors from time to time, and shall provide evidence of any such action
so taken to each of the Investors.
(c) Listing/DTC.
The Company shall promptly secure the listing of all of the Securities to be issued to each Investor hereunder on the Principal Market
(subject to official notice of issuance) and upon each other national securities exchange or automated quotation system, if any, upon
which the Common Stock is then listed, and shall use commercially reasonable efforts to maintain, so long as any shares of Common Stock
shall be so listed, such listing of all such Securities. The Company shall use commercially reasonable efforts to maintain the listing
of the Common Stock on the Principal Market and shall comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of its Subsidiaries shall take any
action that would reasonably be expected to result in the delisting or suspension of the Common Stock on the Principal Market. The Company
shall pay all fees and expenses in connection with satisfying its obligations under this Section 5(c). The Company shall
take all action necessary to ensure that its Common Stock can be transferred electronically as DWAC Shares.
(d) Insider
Trading and Public Disclosure Laws. Each Investor acknowledges that such Investor has become aware of material, non-public information
concerning the Company in the course of the discussions regarding the transactions contemplated herein. Accordingly, such Investor agrees
not to: (i) disclose or “tip” material, non-public information concerning the Company to any person or entity, (ii) effect
or participate in any trading of any securities (or beneficial ownership thereof) of the Company while in possession of material, non-public
information concerning the Company or (iii) take any action that might force the Company to make a public announcement under applicable
securities laws.
(e) Reserved.
(f) Reserved.
(g) Taxes.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investors made under this Agreement.
(h) Securities
Law Compliance. For so long as any Investor holds any Securities, the Company shall (a) take all action necessary to
cause the Common Stock to continue to be registered as a class of securities under Sections 12(g) or 12(b) of the Exchange
Act, shall comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file any document
(whether or not permitted by the Exchange Act) to terminate or suspend such registration or to terminate or suspend its reporting and
filing obligations under the Exchange Act, and (b) prepare and file with the SEC, at the Company’s expense, such amendments
(including, without limitation, post-effective amendments) to the Registration Statement and such Prospectus Supplements pursuant to
Rule 424(b) under the Securities Act, in each case, as may be necessary to keep the Registration Statement effective, and to
keep the Registration Statement and the Prospectus current and available for issuances and sales of all of the Securities by the Company
to the Investor. Each Investor shall furnish to the Company such information regarding itself, its Affiliates, the Securities beneficially
owned by it and the intended method of distribution thereof as shall be reasonably requested by the Company in connection with the preparation
and filing of any such amendment to the Registration Statement or any such Prospectus Supplement, and shall otherwise cooperate with
the Company as reasonably requested by the Company in connection with the preparation and filing of any such amendment to the Registration
Statement or any such Prospectus Supplement. The Company shall comply with all applicable federal, state and foreign securities laws
in connection with the offer, issuance and sale by the Company of the Securities contemplated by the Transaction Documents. Without limiting
the generality of the foregoing, neither the Company nor any of its officers, directors or Affiliates will take, directly or indirectly,
any action designed or intended to stabilize or manipulate the price of any security of the Company, or which would reasonably be expected
to cause or result in, stabilization or manipulation of the price of any security of the Company.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(i) Integration.
From and after the date of this Agreement, neither the Company, nor any of its Affiliates will, and the Company shall use its reasonable
best efforts to ensure that no Person acting on any of their behalf will, directly or indirectly, make any offers or sales of any security
or solicit any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
other offerings of securities by the Company in a manner that would require stockholder approval pursuant to the rules and regulations
of the Principal Market on which any of the securities of the Company are listed or designated, unless stockholder approval is obtained
before the closing of such subsequent transaction in accordance with the rules of such Principal Market.
(j) Use
of Proceeds. The Company will use the net proceeds from the offering of the Securities as described in the Prospectus.
(k) Other
Transactions. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction
in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform
its obligations under any of the Transaction Documents to which it is a party, including, without limitation, the obligation of the Company
to deliver the Securities to the Investors in accordance with the terms of this Agreement.
(l) Subsequent
Equity Issuances. From and after the date of this Agreement until sixty (60) days following the Closing Date (the “Restricted
Period”), without the prior written consent of each Investor (which may be granted or withheld in its sole discretion), neither
the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares
of Common Stock or Common Stock Equivalents (or a combination of units thereof), other than in connection with an Exempt Issuance.
Each of the Investors shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such issuance,
which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond
or other security being required. “Common Stock Equivalents” means any securities of the Company or its Subsidiaries
which entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles
the holder thereof to receive, Common Stock. “Exempt Issuance” means the issuance of (i) Shares to the Investors
pursuant to this Agreement, (ii) shares of Common Stock, Common Stock Equivalents or other securities to any of the Investors pursuant
to any other existing or future contract, agreement or arrangement between the Company and such Investor, (iii) shares of Common
Stock, Common Stock Equivalents or other securities upon the exercise, exchange or conversion of any shares of Common Stock, Common Stock
Equivalents or other securities held by any of the Investors at any time, (iv) the issuances of equity-based awards pursuant to
an Approved Stock Plan (as defined below), and the issuances of shares of Common Stock upon the exercise or conversion of any such equity-based
awards, provided that during the Restricted Period, the exercise or conversion price of any such equity-based award is not lowered, none
of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such equity-based
award are otherwise materially changed in any manner that adversely affects any of the Investors, (v) shares of Common Stock issued
upon the conversion or exercise of Common Stock Equivalents (other than equity-based awards issued pursuant to an Approved Stock Plan
that are covered by clause (iv) above) issued and outstanding on the date hereof, provided that the conversion, exercise or other
method of issuance (as the case may be) of any such Common Stock Equivalent is made solely pursuant to the conversion, exercise or other
method of issuance (as the case may be) provisions of such Common Stock Equivalent that were in effect on the date of this Agreement,
and during the Restricted Period the conversion, exercise or issuance price of any such Common Stock Equivalents (other than equity-based
awards issued pursuant to an Approved Stock Plan that are covered by clause (iv) above) is not lowered, none of such Common Stock
Equivalents (other than equity-based awards issued pursuant to an Approved Stock Plan that are covered by clause (iv) above) are
amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Common Stock Equivalents
(other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (iv) above)
are otherwise materially changed in any manner that adversely affects any of the Investors, and (vi) shares of Common Stock issued
pursuant to the Company’s existing at-the-market facility with Jefferies LLC. “Approved Stock Plan” means any
employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the date hereof.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
6. TRANSFER.
On the Closing Date, the
Company shall issue the Securities in accordance with the terms of this Agreement. All Purchase Shares to be issued to or for the benefit
of the Investors pursuant to this Agreement shall be issued as DWAC Shares. The Company shall deliver a Warrant registered in the name
of such Investor to purchase up to the number of shares of Common Stock as set forth on Schedule I hereto. The Company represents
and warrants to each of the Investors that the Purchase Shares shall be freely transferable on the books and records of the Company.
Certificates and any other instruments evidencing the Securities shall not bear any restrictive or other legend. If any Investor effects
a sale, assignment or transfer of the Securities, the Company shall permit the transfer and shall promptly issue DWAC Shares in such
name and in such denominations as specified by such Investor to effect such sale, transfer or assignment. The Company acknowledges that
a breach by it of its obligations hereunder will cause irreparable harm to the Investors. Accordingly, the Company acknowledges that
the remedy at law for a breach of its obligations under this Section 6 will be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Section 6, that each of the Investors shall be entitled, in
addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer,
without the necessity of showing economic loss and without any bond or other security being required. The Company shall take all actions
to carry out the intent and accomplish the purposes of this Section 6, including, without limitation, delivering or causing
to be delivered all such legal opinions, consents, certificates, and resolutions as necessary or desirable to carry out the intent and
accomplish the purposes of this Section 6. Any fees associated with the issuance of such legal opinions, consents, certificates,
resolutions and instructions shall be borne by the Company.
| 7. | CONDITIONS
TO THE COMPANY’S OBLIGATION TO ISSUE AND SELL THE SECURITIES. |
The obligation of the Company
hereunder to issue and sell the Securities to the Investors on the Closing Date is subject to the satisfaction or, where legally permissible,
the waiver of each of the following conditions:
(a) Each
of the Investors shall have executed this Agreement and delivered the same to the Company;
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(b) No
stop order with respect to the Registration Statement shall be pending or threatened by the SEC;
(c) The
representations and warranties of the Investors shall be true and correct in all material respects as of the date hereof and as of the
Closing Date as though made at that time; and
(d) Each
of the Investors shall have previously delivered to the Escrow Agent such Investor’s Subscription Amount in accordance with Section 2(b) hereof.
| 8. | CONDITIONS
TO THE INVESTORS’ SEVERAL AND NOT JOINT OBLIGATION TO PURCHASE THE SECURITIES. |
The several and not joint
obligation of each Investor under this Agreement to purchase the number of Securities set forth opposite its name on Schedule I
hereto is subject to the satisfaction or, where legally permissible, the waiver of each of the following conditions:
(a) The
Company shall have executed each of the Transaction Documents to which it is a party and delivered the same to each of the Investors;
(b) The
Common Stock shall be listed or quoted on the Principal Market, trading in the Common Stock shall not have been within the last 365 days
suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investors pursuant to this Agreement
shall have been, if applicable, approved for listing or quotation on the Principal Market in accordance with the applicable rules and
regulations of the Principal Market, subject only to official notice of issuance;
(c) The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section 4 above, in which case, the portion of such
representations and warranties so qualified shall be true and correct without further qualification) as of the date hereof and as of
the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall
be true and correct as of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior
to the Closing Date.
(d) The
Registration Statement shall be effective and no stop order with respect to the Registration Statement shall be pending or threatened
by the SEC. The Company shall have a maximum dollar amount certain of securities, including the Securities, registered under the Registration
Statement which is sufficient to issue to the Investors not less than all of the Securities to be purchased under this Agreement. The
Initial Prospectus Supplement shall have been filed with the SEC. The Prospectus shall be current and available for the issuance
and sale of all of the Securities by the Company to the Investors. Any other Prospectus Supplements required to have been filed by the
Company with the SEC under the Securities Act at or prior to the Closing Date shall have been filed with the SEC within the applicable
time periods prescribed for such filings under the Securities Act. All reports, schedules, registrations, forms, statements, information
and other documents required to have been filed by the Company with the SEC at or during the 12-month period immediately preceding the
Closing Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable time
periods prescribed for such filings under the Exchange Act, including any applicable extension periods contemplated by the Exchange Act;
(e) The
Company shall be eligible to transfer its Common Stock, electronically as DWAC Shares;
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(f) All
federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction
Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders
of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state and local
regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the consummation
of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made, including, without limitation,
in each case those required under the Securities Act, the Exchange Act, applicable state securities or “Blue Sky” laws or
applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market or any state securities
regulators;
(g) No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation of
or which would materially modify or delay any of the transactions contemplated by the Transaction Documents;
(h) No
action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental
authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors or
Affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking
material damages in connection with such transactions;
(i) No
Person shall have commenced a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;
(j) The
Company, pursuant to or within the meaning of any Bankruptcy Law, shall not have (i) commenced a voluntary case, (ii) consented
to the entry of an order for relief against it in an involuntary case, (iii) consented to the appointment of a Custodian of it or
for all or substantially all of its property, or (iv) made a general assignment for the benefit of its creditors or is generally
unable to pay its debts as the same become due; and
(k) A
court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (i) is for relief against
the Company in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or
(iii) orders the liquidation of the Company or any Subsidiary.
(l) The
Company shall have provided each Investor with the wire instructions that are specified in the Escrow Agreement on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
In consideration of the Investors’
execution and delivery of this Agreement and acquiring the Securities, and in addition to all of the Company's other obligations under
the Transaction Documents to which it is a party, the Company shall defend, protect, indemnify and hold harmless each Investor and all
of its Affiliates, stockholders, officers, directors and employees and any of the foregoing Person's agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by the Transaction Documents) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties,
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action
for which indemnification hereunder is sought), and including reasonable attorneys' fees and disbursements (the “Indemnified
Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to: (a) any misrepresentation
or breach of any representation or warranty made by the Company in any of the Transaction Documents or any other certificate, instrument
or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in
any of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (c) any cause
of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance
or enforcement of any of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (d) any
violation of the Securities Act, the Exchange Act, state securities or “Blue Sky” laws, or the rules and regulations
of the Principal Market in connection with the transactions contemplated by the Transaction Documents by the Company or any of its Affiliates,
officers, directors or employees, (e) any untrue statement or alleged untrue statement of a material fact contained, or incorporated
by reference, in the Registration Statement or any amendment thereto or any omission or alleged omission to state therein, or in any
document incorporated by reference therein, a material fact required to be stated therein or necessary to make the statements therein
not misleading, or (f) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference,
in the Prospectus, or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading; provided, however, that (I) the indemnity contained in clause (c) of this Section 9 shall not apply
to any Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct of an Indemnitee,
(II) the indemnity contained in clauses (d), (e) and (f) of this Section 9 shall not apply to any Indemnified
Liabilities of an Investor to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by
or on behalf of such Investor expressly for use in any Prospectus Supplement, if the Prospectus was timely made available by the Company
to such Investor pursuant to Section 5(h), (III) the indemnity contained in clauses (d), (e) and (f) of this
Section 9 shall not inure to the benefit of an Investor to the extent such Indemnified Liabilities are based on a failure
of such Investor to deliver or to cause to be delivered the Prospectus made available by the Company, if such Prospectus was timely made
available by the Company pursuant to Section 5(h), and if delivery of the Prospectus by such Investor was required under
the Securities Act with respect to the Securities and such delivery by such Investor would have cured the defect giving rise to such
Indemnified Liabilities, and (IV) the indemnity in this Section 9 shall not apply to amounts paid in settlement of any
claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld,
conditioned or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under
applicable law. Any required indemnification payment for any particular claim shall be made within thirty (30) days from the date an
Investor makes a written request for it. A certificate containing reasonable detail as to the amount of such indemnification submitted
to the Company by an Investor shall be conclusive evidence, absent manifest error, of the amount due from the Company to such Investor.
If any action shall be brought against any Indemnitee in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee
shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its
own choosing reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except
to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the
reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position
of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate
counsel.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
10. RESERVED.
11. TERMINATION
This Agreement may be terminated
only as follows:
(a) If
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a
general assignment for the benefit of its creditors, this Agreement shall automatically terminate without any liability or payment to
the Company (except as set forth below) without further action or notice by any Person.
(b) In
the event that the Closing shall not have occurred on or before the Closing Date, due to the failure to satisfy the conditions set forth
in Sections 7 and 8 above with respect to the Closing, either the Company, on the one hand, or any Investor, on the other hand,
shall have the option to terminate this Agreement at the close of business on such date or thereafter without liability of any party
to any other party (except as set forth below); provided, however, that the right to terminate this Agreement under this Section 11(b) shall
not be available to any party if such party is then in breach of any covenant or agreement contained in this Agreement or any representation
or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set forth in Section 7(c) or
Section 8(c), as applicable, could not then be satisfied. Any termination of this Agreement pursuant to this Section 11(b) shall
be effected by written notice from the Company to each of the Investors, or any Investor to the Company and each of the other Investors,
as the case may be, setting forth the basis for the termination hereof.
The representations and warranties and covenants
of the Company and the Investors contained in Sections 3, 4, 5, and 6 hereof, the indemnification provisions
set forth in Section 9 hereof and the agreements and covenants set forth in Sections 10, 11 and 12,
shall survive the Closing and any termination of this Agreement. No termination of this Agreement shall be deemed to release the Company
or any Investor from any liability for intentional misrepresentation or willful breach by such party of any of the Transaction Documents
to which it is a party.
12. MISCELLANEOUS.
(a) Governing
Law; Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall govern all issues concerning the relative rights
of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this
Agreement and the other Transaction Documents shall be governed by the internal laws of the State of New Jersey, without giving effect
to any choice of law or conflict of law provision or rule (whether of the State of New Jersey or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New Jersey. Each party hereby irrevocably submits to the
exclusive jurisdiction of the state and federal courts sitting in the State of New Jersey for the adjudication of any dispute hereunder
or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under
this Agreement and the other Transaction Documents and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by
law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER TRANSACTION DOCUMENTS OR ANY
TRANSACTION CONTEMPLATED HEREBY OR THEREBY.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(b) Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature
or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be
binding upon the signatory thereto with the same force and effect as if the signature were an original signature.
(c) Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
(d) Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction.
(e) Entire
Agreement; Amendment. This Agreement and the other Transaction Documents supersede all other prior oral or written agreements among
the Investors, the Company, their respective Affiliates and Persons acting on their behalf with respect to the subject matter hereof,
and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor
any of the Investors makes any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges
and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly
set forth in the Transaction Documents. No provision of this Agreement or the other Transaction Documents may be amended other than by
a written instrument signed by each of the parties hereto or thereto.
(f) Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent
by facsimile or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses for such communications shall be:
If to the Company:
CytoSorbents Corporation
305 College Road East
Princeton, New Jersey 08540
Attention: Dr. Phillip
P. Chan, Chief Executive Officer
Fax No: (732) 329-8650
E-mail address: pchan@cytosorbents.com
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
with a copy (which shall not constitute
notice) to:
Morgan, Lewis & Bockius LLP
502 Carnegie Center
Princeton, New Jersey 08540-6289
Attention: David C. Schwartz, Esq.
Fax No: (609) 919-6701
E-mail address: david.schwartz@morganlewis.com
If to an Investor, to its address set
forth opposite its name on Schedule I hereto, with copies to such Investor’s representatives as set forth on Schedule
I hereto,
or at such other address and/or facsimile number
and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party three (3) Business
Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender's facsimile machine or email account containing
the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission
or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt
by facsimile or email or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or
(iii) above, respectively.
(g) Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and any permitted successors and assigns
of the Company. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each of the Investors, including by merger or consolidation. None of the Investors may assign its rights or obligations under this
Agreement.
(h) No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and any permitted successors and assigns
of the Company and, except as set forth in Section 9, is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.
(i) Publicity.
No Investor shall issue a press release or any other public disclosure regarding this Agreement or the substance hereof without the prior
written consent of the Company.
(j) Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(k) Financial
Advisor, Placement Agent, Broker or Finder. Except for B. Riley Securities, Inc., whom the Company has engaged to serve as a
financial advisor in connection with the transactions contemplated herein, the Company represents and warrants to each of the Investors
that it has not engaged any other financial advisor, placement agent, broker or finder in connection with the transactions contemplated
hereby. Each Investor, severally and only with respect to itself and not jointly, represents and warrants to the Company that it has
not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Company
shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder
relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold each of the Investors harmless against,
any liability, loss or expense (including, without limitation, attorneys' fees and out of pocket expenses) arising in connection with
any such claim.
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(l) No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.
(m) Remedies,
Other Obligations, Breaches and Injunctive Relief. The Investors’ remedies provided in this Agreement, including, without limitation,
the Investors’ remedies provided in Section 9, shall be cumulative and in addition to all other remedies available
to the Investors under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief),
no remedy of any of the Investors contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy
and nothing herein shall limit any Investor's right to pursue actual damages for any failure by the Company to comply with the terms
of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investors
and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach
or threatened breach, any Investor shall be entitled, in addition to all other available remedies, to an injunction restraining any breach,
without the necessity of showing economic loss and without any bond or other security being required.
(n) Enforcement
Costs. If: (i) this Agreement is placed by any Investor in the hands of an attorney for enforcement or is enforced by any Investor
through any legal proceeding; (ii) an attorney is retained to represent any Investor in any bankruptcy, reorganization, receivership
or other proceedings affecting creditors' rights and involving a claim under this Agreement; or (iii) an attorney is retained to
represent any Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall pay to such Investor,
as incurred by such Investor, all reasonable costs and expenses including attorneys' fees incurred in connection therewith, in addition
to all other amounts due hereunder. If this Agreement is placed by the Company in the hands of an attorney for enforcement against an
Investor or is enforced by the Company against an Investor through any legal proceeding, then such Investor against whom this Agreement
is so enforced shall pay to the Company, as incurred by the Company, all reasonable costs and expenses including reasonable attorneys’
fees incurred in connection therewith, in addition to all other amounts due hereunder.
(o) Waivers.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such
waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other
right, power or privilege.
(p) Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under the Transaction Documents are several and
not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken
by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors
do not so constitute, a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that
the Investors are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Investors are not acting in concert or as a group,
and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction
Documents. The decision of each Investor to purchase Securities pursuant to the Transaction Documents has been made by such Investor
independently of any other Investor. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection
with such Investor making its investment hereunder and that no other Investor will be acting as agent of such Investor in connection
with monitoring such Investor’s investment in the Securities or enforcing its rights under the Transaction Documents. The Company
and each Investor confirms that each Investor has independently participated with the Company in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. Each Investor shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be
necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The use of a single agreement
to effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of the Company, not the action or
decision of any Investor, and was done solely for the convenience of the Company and not because it was required or requested to do so
by any Investor. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and
among the Investors.
* * * * *
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
THE COMPANY: |
|
|
|
CytoSorbents Corporation |
|
|
|
By: |
/s/ Dr. Phillip P. Chan |
|
Name: Dr. Phillip P. Chan |
|
Title: Chief Executive Officer |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Phillip P. Chan |
|
|
|
By: |
/s/ Phillip P. Chan |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Kathleen P. Bloch |
|
|
|
By: |
/s/ Kathleen P. Bloch |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Michael G. Bator |
|
|
|
By: |
/s/ Michael G. Bator |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Efthymios N. Deliargyris |
|
|
|
By: |
/s/ Efthymios N. Deliargyris |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Alan D. Sobel |
|
|
|
By: |
/s/ Alan D. Sobel |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Vincent J. Capponi |
|
|
|
By: |
/s/ Vincent J. Capponi |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
James E. Cason |
|
|
|
By: |
/s/ James E. Cason |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Thomas D. Golobish |
|
|
|
By: |
/s/ Thomas D. Golobish |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Edward R. Jones |
|
|
|
By: |
/s/ Edward R. Jones |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
|
|
INVESTORS: |
|
|
|
Jiny Kim |
|
|
|
By: |
/s/
Jiny Kim |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Irina B. Kulinets |
|
|
|
By: |
/s/ Irina B. Kulinets |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Bettina Sabisch |
|
|
|
By: |
/s/ Bettina Sabisch |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Dechomai Asset Trust |
|
|
|
By: |
/s/ Ryan Raffin |
|
Name: Ryan Raffin |
|
Title: Trustee |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Harbour Holdings Ltd. |
|
|
|
By: |
/s/ Virginia Shaffar |
|
Name: Virginia Shaffar |
|
Title: Vice President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Skylands Special Investment LLC |
|
|
|
By: |
Skylands Capital, LLC, Managing Member |
|
|
|
By: |
/s/ Virginia Shaffar |
|
Name: Virginia Shaffar |
|
Title: Vice President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Skylands Quest LLC |
|
|
|
By: Skylands Capital, LLC, Managing
Member |
|
|
|
By: |
/s/ Virginia Shaffar |
|
Name: Virginia Shaffar |
|
Title: Vice President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Skylands Special Investment II
LLC |
|
|
|
By: Skylands Capital, LLC, Managing
Member |
|
|
|
By: |
/s/ Virginia Shaffar |
|
Name: Virginia Shaffar |
|
Title: Vice President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Tech Council Ventures II LP |
|
|
|
By: |
/s/ Stephen Socolof |
|
Name: Stephen Socolof |
|
Title: Partner |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Tech Council Ventures II-AI LP |
|
|
|
By: |
/s/ Stephen Socolof |
|
Name: Stephen Socolof |
|
Title: Partner |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
ROKK LLC |
|
|
|
By: |
/s/ Mary Shipley Ley |
|
Name: Mary Shipley Ley |
|
Title: Member Manager |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Mary Shipley Ley |
|
|
|
By: |
/s/ Mary Shipley Ley |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Lee Alan Shipley |
|
|
|
By: |
/s/ Lee Alan Shipley |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Reed Robert Shipley |
|
|
|
By: |
/s/ Reed Robert Shipley |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Neuberger Berman Equity Funds
- Neuberger Berman Intrinsic Value Fund |
|
|
|
By: Neuberger Berman Investment
Advisers LLC, its Investment Manager |
|
|
|
By: |
/s/
Benjamin H. Nahum |
|
Name: Benjamin H. Nahum |
|
Title: Managing Director |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Nahum Family Investments LLC |
|
|
|
By: |
/s/ Benjamin H. Nahum |
|
Name: Benjamin H. Nahum |
|
Title: Manager |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
AG Family L.P. |
|
|
|
GLMS, General Partner |
|
|
|
By: |
/s/ Thomas A. Satterfield, Jr. |
|
Name: Thomas A. Satterfield, Jr. |
|
Title: President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
|
|
INVESTORS: |
|
|
|
Calm Waters Partnership |
|
|
|
By: |
/s/ Richard S. Strong |
|
Name: Richard S. Strong |
|
Title: Managing Partner |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Sean X. Wang |
|
|
|
By: |
/s/ Sean X. Wang |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
|
|
INVESTORS: |
|
|
|
Brian A. Pryor |
|
|
|
By: |
/s/ Brian A. Pryor |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Lincoln Park Capital Fund, LLC |
|
|
|
By: |
/s/ Joshua Scheinfeld |
|
Name: Joshua Scheinfeld |
|
Title: Manager of Managing Member |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Tomsat Investment & Trading Co, Inc |
|
|
|
By: |
/s/ Thomas A. Satterfield, Jr. |
|
Name: Thomas A. Satterfield, Jr. |
|
Title: President |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.
|
INVESTORS: |
|
|
|
Mark Kolb |
|
|
|
By: |
/s/
Mark Kolb |
[Signature
Page to the Securities Purchase Agreement]
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
SCHEDULE I
Investors
Investor | |
Investor Address | |
Purchase
Shares | | |
Shares
underlying
Warrant | | |
Subscription
Amount | | |
State of Residency
or Organization |
Dechomai Asset Trust | |
[***] | |
| 1,503,760 | | |
| 526,316 | | |
$ | 2,000,000.80 | | |
[***] |
Harbour Holdings Ltd. | |
[***] | |
| 72,031 | | |
| 25,210 | | |
$ | 95,801.23 | | |
[***] |
Skylands Special Investment LLC | |
[***] | |
| 689,098 | | |
| 241,184 | | |
$ | 916,500.34 | | |
[***] |
Skylands Quest LLC | |
[***] | |
| 229,098 | | |
| 80,184 | | |
$ | 304,700.34 | | |
[***] |
Skylands Special Investment II LLC | |
[***] | |
| 137,594 | | |
| 48,157 | | |
$ | 183,000.02 | | |
[***] |
Tech Council Ventures II LP | |
[***] | |
| 902,482 | | |
| 315,868 | | |
$ | 1,200,301.06 | | |
[***] |
Tech Council Ventures II-AI LP | |
[***] | |
| 225,339 | | |
| 78,868 | | |
$ | 299,700.87 | | |
[***] |
ROKK LLC | |
[***] | |
| 676,692 | | |
| 236,842 | | |
$ | 900,000.36 | | |
[***] |
Mary Shipley Ley | |
[***] | |
| 526,316 | | |
| 184,210 | | |
$ | 700,000.28 | | |
[***] |
Lee Alan Shipley | |
[***] | |
| 526,316 | | |
| 184,210 | | |
$ | 700,000.28 | | |
[***] |
Reed Robert Shipley | |
[***] | |
| 526,316 | | |
| 184,210 | | |
$ | 700,000.28 | | |
[***] |
Neuberger Berman Equity Funds - Neuberger Berman Intrinsic Value Fund | |
[***] | |
| 375,940 | | |
| 131,579 | | |
$ | 500,000.20 | | |
[***] |
Nahum Family Investments LLC | |
[***] | |
| 37,594 | | |
| 13,157 | | |
$ | 50,000.02 | | |
[***] |
AG Family L.P. | |
[***] | |
| 263,158 | | |
| 92,105 | | |
$ | 350,000.14 | | |
[***] |
Calm Waters Partnership | |
[***] | |
| 150,376 | | |
| 52,631 | | |
$ | 200,000.08 | | |
[***] |
Sean X. Wang | |
[***] | |
| 187,970 | | |
| 65,789 | | |
$ | 250,000.10 | | |
[***] |
Brian A. Pryor | |
[***] | |
| 37,594 | | |
| 13,157 | | |
$ | 50,000.02 | | |
[***] |
Lincoln Park Capital, LLC | |
[***] | |
| 150,376 | | |
| 52,631 | | |
$ | 200,000.08 | | |
[***] |
Tomsat Investment & Trading Co, Inc. | |
[***] | |
| 112,782 | | |
| 39,473 | | |
$ | 150,000.06 | | |
[***] |
Mark Kolb | |
[***] | |
| 75,188 | | |
| 26,315 | | |
$ | 100,000.04 | | |
[***] |
Phillip P. Chan | |
[***] | |
| 75,188 | | |
| 26,315 | | |
$ | 100,000.04 | | |
[***] |
Kathleen P. Bloch | |
[***] | |
| 37,594 | | |
| 13,157 | | |
$ | 50,000.02 | | |
[***] |
Michael G. Bator | |
[***] | |
| 37,594 | | |
| 13,157 | | |
$ | 50,000.02 | | |
[***] |
Efthymios N. Deliargyris | |
[***] | |
| 22,557 | | |
| 7,894 | | |
$ | 30,000.81 | | |
[***] |
Alan D. Sobel | |
[***] | |
| 22,557 | | |
| 7,894 | | |
$ | 30,000.81 | | |
[***] |
Vincent J. Capponi | |
[***] | |
| 18,797 | | |
| 6,578 | | |
$ | 25,000.01 | | |
[***] |
James E. Cason | |
[***] | |
| 18,797 | | |
| 6,578 | | |
$ | 25,000.01 | | |
[***] |
Thomas D. Golobish | |
[***] | |
| 15,038 | | |
| 5,263 | | |
$ | 20,000.54 | | |
[***] |
Edward R. Jones | |
[***] | |
| 7,519 | | |
| 2,631 | | |
$ | 10,000.27 | | |
[***] |
Jiny Kim | |
[***] | |
| 7,519 | | |
| 2,631 | | |
$ | 10,000.27 | | |
[***] |
Irina B. Kulinets | |
[***] | |
| 7,519 | | |
| 2,631 | | |
$ | 10,000.27 | | |
[***] |
Bettina Sabisch | |
[***] | |
| 56,391 | | |
| 19,736 | | |
$ | 75,000.03 | | |
[***] |
TOTAL | |
| |
| 7,733,090 | | |
| 2,706,561 | | |
$ | 10,285,009.70 | | |
|
Information in this exhibit identified by [***]
is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K.
EXHIBIT A
Warrant
[attached separately]
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From May 2024 to Jun 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Jun 2023 to Jun 2024